Detailed Information on Publication Record
2020
Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept
BOŘILOVÁ LINHARTOVÁ, Petra, Daniela GACHOVÁ and Břetislav LIPOVÝBasic information
Original name
Responsiveness to i.v. immunoglobulin therapy in patients with toxic epidermal necrolysis: A novel pharmaco-immunogenetic concept
Authors
BOŘILOVÁ LINHARTOVÁ, Petra (203 Czech Republic, belonging to the institution), Daniela GACHOVÁ (203 Czech Republic, belonging to the institution) and Břetislav LIPOVÝ (203 Czech Republic, guarantor, belonging to the institution)
Edition
JOURNAL OF DERMATOLOGY, HOBOKEN, WILEY, 2020, 0385-2407
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30216 Dermatology and venereal diseases
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 4.005
RIV identification code
RIV/00216224:14110/20:00116596
Organization unit
Faculty of Medicine
UT WoS
000571617900001
Keywords in English
Fas receptor; gene variability; i; v; immunoglobulin therapy; pharmaco-immunogenetics; toxic epidermal necrolysis
Tags
International impact, Reviewed
Změněno: 7/2/2022 10:07, Mgr. Tereza Miškechová
Abstract
V originále
Toxic epidermal necrolysis (TEN) represents a rare drug-induced autoimmune reaction with delayed-type hypersensitivity that initiates the process of developing massive keratinocyte apoptosis, dominantly in the dermoepidermal junction. Although the etiopathophysiology has not yet been fully elucidated, the binding of Fas ligand (FasL, CD95L) to the Fas receptor (CD95) was shown to play a key role in the induction of apoptosis in this syndrome. The knowledge of the role of immunoglobulin G (IgG) in inhibition of Fas-mediated apoptosis contributed to the introduction of i.v. Ig (IVIg) in the therapy of TEN patients. Despite great enthusiasm for this therapy at the end of the 1990s, subsequent studies in various populations and meta-analyses could not unequivocally confirm the efficacy of the IVIg-based treatment concept. Today, therefore, we are faced with the dilemmas of how to adjust therapy of TEN patients most effectively, which patients could benefit from IVIg therapy and what dose of the preparation should be administrated. The ground-breaking question is: do the host genetic profiles influence the responsiveness and side-effects of IVIg therapy in TEN patients? Based on recent pharmacological, immunological and genetic findings, we suggest that the variability of IVIg therapy outcomes in TEN patients may be related to functional variants inFas,FasLand Fc-gamma receptor genes. This novel concept could lead to improved quality of care for patients with TEN, facilitating personalized therapy to reduce mortality.
Links
| ROZV/28/LF5/2020, interní kód MU |
|